Sugi Predict

Sugi Predict / Compounds / SCHEMBL1702676

SCHEMBL1702676

SCHEMBL1702676

Nc1ccc(B(O)O)c(F)c1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ ENPP2 Q13822 1/20 0.40
▸ LMNA P02545 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ GFER P55789 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ TSHR P16473 3/20 0.37
▸ CASP1 P29466 2/20 0.37
▸ CYP3A4 P08684 2/20 0.37
▸ PDE10A Q9Y233 1/20 0.37
▸ TAAR1 Q96RJ0 1/20 0.33
▸ ADRA2B P18089 1/20 0.33
▸ CA1 P00915 1/20 0.32
▸ CA2 P00918 1/20 0.32
▸ GLA P06280 1/20 0.31
▸ POLB P06746 1/20 0.31
▸ GAA P10253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29631566 1.00 ALDH1A1 (0.40) ALDH1A1KDM4EENPP2LMNAMAPT
SCHEMBL29278211 0.90 ALDH1A1 (0.34) ALDH1A1KDM4EENPP2LMNAMAPT
SCHEMBL2786252 0.82 ALDH1A1 (0.40) ALDH1A1KDM4EENPP2LMNAMAPT
SCHEMBL29517809 0.82 ALDH1A1 (0.40) ALDH1A1KDM4EENPP2LMNAMAPT
Hydrochloric Acid SCHEMBL29951492 0.80 ALDH1A1 (0.39) ALDH1A1KDM4EENPP2LMNAMAPT
SCHEMBL28824845 0.77 — —
SCHEMBL12384874 0.76 ESR2 (0.36) KDM4ELMNA
SCHEMBL39406 0.76 CES2 (0.43) ALDH1A1MAPTTDP1POLB
SCHEMBL29395656 0.76 CES2 (0.43) ALDH1A1MAPTTDP1POLB
SCHEMBL14287217 0.76 CASP1 (0.48) ALDH1A1KDM4EENPP2MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111574426-A Diamine monomer containing isoindigo structure and black polyimide synthesized from diamine monomer 湘潭大学 2020-08-25 — — CN claimed
CN-119504808-A Compound, preparation method and application thereof 四川科伦药物研究院有限公司 2025-02-25 — — CN disclosed
CN-110627796-B Nitrogenous heterocyclic derivative and application thereof in medicine 北京越之康泰生物医药科技有限公司 2022-07-12 — — CN disclosed
CN-110627796-A Nitrogenous heterocyclic derivative and application thereof in medicine 北京越之康泰生物医药科技有限公司 2019-12-31 — — CN disclosed
CN-108026050-A NOVEL COMPOUNDS AS ROR GAMMA MODULATORS 格兰马克药品股份有限公司 2018-05-11 — — CN disclosed
CN-103687595-B Novel compounds as diacylglycerol acyltransferase inhibitors 葛兰素史密斯克莱知识产权（第2 号）有限公司 2017-05-24 — — CN disclosed
EP-2723332-B1 NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2016-03-02 — — EP disclosed
US-9242929-B2 Compounds as diacylglycerol acyltransferase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2016-01-26 — — US disclosed
US-20150307445-A1 Novel Compounds as Diacylglycerol Acyltransferase Inhibitors GlaxoSmith Kline Intellectual Property (No.2) Limited (GB) 2015-10-29 — — US disclosed
EP-2440528-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2014-10-08 — — EP disclosed
EP-2723332-A1 NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2014-04-30 — — EP disclosed
US-8487103-B2 Quinoline inhibitors of hepatitis C virus polymerase ROCHE PALO ALTO LLC (US) 2013-07-16 — — US disclosed
WO-2012162127-A1 NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2012-11-29 — — WO disclosed
EP-2440528-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2012-04-18 — — EP disclosed
US-20110300103-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC (US) 2011-12-08 — — US disclosed
US-8026253-B2 Quinoline inhibitors of HCV polymerase ROCHE PALO ALTO LLC (US) 2011-09-27 — — US disclosed
WO-2010142656-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-12-16 — — WO disclosed
US-20100311760-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS DE VICENTE FIDALGO JAVIER 2010-12-09 — — US disclosed
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2010-04-08 — — US disclosed
EP-1914221-A1 PROCESS FOR PRODUCING BIARYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-04-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311760-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS EIF2AK2, XDH, GTF3C4 ALDH1A1 1266/4885KDM4E 1276/4885ENPP2 2777/4885
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND NISCH, BLVRB, BBOX1 ALDH1A1 4339/4885KDM4E 2606/4885ENPP2 1920/4885
US-20110300103-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS EIF2AK2, ZC3HAV1, IRF3 ALDH1A1 2014/4885KDM4E 1344/4885ENPP2 3275/4885
US-20150307445-A1 Novel Compounds as Diacylglycerol Acyltransferase Inhibitors DGAT1, DGAT2, LCAT ALDH1A1 945/4885KDM4E 3858/4885ENPP2 837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.